We all know that a healthy, balanced diet dominated by unprocessed foods is a recipe for gut and overall health, but ...

Valneva has announced positive outcomes from its Phase III VLA1553-321 trial of the single-shot IXCHIQ chikungunya virus ...

ADRs traded higher in the premarket on Tuesday after the French biotech posted additional data for its FDA-approved ...

Valneva’s growth potential lies in Ixchiq, but risks remain. Find out why VALN stock is still a Buy with a good long-term ...

Valneva’s vaccine was highly immunogenic in both dose groups. A full dose of the vaccine exhibited a more robust immune response compared to a half dose by providing protective antibody titers already ...

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported further positive Phase 3 data in adolescents for its single-shot chikungunya virus (CHIKV) vaccine, IXCHIQ ® ...

lasting three to seven days and can be mistaken for other mosquito transmitted virus diseases such as zika, dengue, and chikungunya. Death cases have been reported in several states and others are ...

New vaccines against meningococci, pneumococci and the chikungunya virus will soon be available in Austria. This was ...

Climate change could wreak havoc on Britain in coming decades, with rising food poisoning, allergies and the arrival of ...

Valneva has announced positive outcomes from its Phase III VLA1553-321 trial of the single-shot IXCHIQ chikungunya virus (CHIKV) vaccine in adolescents. The trial demonstrated a ‘sustained ...